Published in Clin Pharmacol Ther on June 04, 2014
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report. Br J Clin Pharmacol (2015) 0.96
Curcumin: An effective adjunct in patients with statin-associated muscle symptoms? J Cachexia Sarcopenia Muscle (2016) 0.81
PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis (2016) 0.79
Big Data Transforms Discovery-Utilization Therapeutics Continuum. Clin Pharmacol Ther (2016) 0.77
Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol (2016) 0.75
Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study. BMJ Open (2017) 0.75
Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?". MBio (2016) 0.75
Phenotyping Adverse Drug Reactions: Statin-Related Myotoxicity. AMIA Jt Summits Transl Sci Proc (2015) 0.75
Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4? CMAJ (2015) 0.75
PharmGKB summary: very important pharmacogene information for RYR1. Pharmacogenet Genomics (2016) 0.75
Statin-Associated Muscle Adverse Events: Update for clinicians. Sultan Qaboos Univ Med J (2016) 0.75
Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J (2016) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med (2002) 6.85
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther (2005) 5.41
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 5.25
Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation (2006) 4.35
Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med (2002) 3.82
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 3.29
Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord (2007) 3.29
Statin safety: a systematic review. Am J Cardiol (2006) 3.14
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
Clinical perspectives of statin-induced rhabdomyolysis. Am J Med (2006) 3.00
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 2.99
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med (2005) 2.80
Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther (2011) 2.50
Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve (2010) 2.48
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther (2010) 2.22
Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol (2004) 2.18
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol (2005) 2.16
Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf (2008) 2.08
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA (1990) 2.05
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther (2006) 1.97
Statin safety: an overview and assessment of the data--2005. Am J Cardiol (2006) 1.91
Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol (2012) 1.88
Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) (2012) 1.83
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 1.75
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol (2005) 1.73
SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther (2013) 1.61
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J (2011) 1.60
Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy (2010) 1.55
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation (2002) 1.51
Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol (2006) 1.50
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther (2004) 1.45
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics (2011) 1.34
Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve (2013) 1.33
Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 1.24
Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink. Br J Clin Pharmacol (2014) 1.14
The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther (2011) 1.12
Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA (2012) 1.12
Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther (2011) 1.10
Statin induced myotoxicity. Eur J Intern Med (2012) 1.08
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol (2006) 1.06
Etiology and frequency of rhabdomyolysis. Pharmacotherapy (2002) 1.00
Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS One (2008) 0.96
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther (2003) 0.96
The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol (2010) 0.94
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther (2001) 0.94
Drug induced rhabdomyolysis. Curr Opin Pharmacol (2012) 0.93
Antiretroviral and statin drug-drug interactions. Cardiol Rev (2008) 0.92
Unusual causes of rhabdomyolysis. Intern Med J (2008) 0.92
Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open (2013) 0.92
Managing statin-induced muscle toxicity in a lipid clinic. J Clin Pharm Ther (2011) 0.88
Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med (2011) 0.88
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag (2005) 0.87
HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients. J Clin Neuromuscul Dis (2001) 0.86
Development of a detection algorithm for statin-induced myopathy using electronic medical records. J Clin Pharm Ther (2013) 0.84
Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther (2011) 0.83
The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Eur Heart J (2012) 0.83
Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother (2000) 0.82
Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet Genomics (2013) 0.80
Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol (1999) 0.79
Preempting and preventing drug-induced liver injury. Nat Genet (2010) 0.79
Is there clinical benefit to routine enzyme testing of patients on statins? Expert Opin Drug Saf (2011) 0.77
Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol (2006) 0.77
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. Angiology (2000) 0.76
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol (2012) 0.76
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther (2014) 1.17
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther (2017) 0.76
Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system. Clin Pharmacol Ther (2014) 0.76